Related Experiment Video
Updated: Jun 3, 2026
11:34
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
[Treatment of hepatitis C]
Marc Bourlière1, Asma Khaloun, Paul Castellani
1Service d'hépato-gastroentérologie, hôpital Saint-Joseph, 13008 Marseille, France. mbourliere@hopital-saint-joseph.fr
La Revue Du Praticien
|April 2, 2011
Summary
Hepatitis C treatment has advanced significantly, with pegylated interferon and ribavirin achieving sustained virological response in over 50% of patients. Future direct antiviral agents promise further improvements in Hepatitis C management.
Area of Science:
- Hepatology
- Virology
- Pharmacology
Background:
- Hepatitis C treatment has seen substantial progress over the past 20 years.
- Current therapies aim to improve sustained virological response (SVR).
Purpose of the Study:
- To review advancements in Hepatitis C treatment.
- To highlight factors contributing to improved treatment outcomes.
- To anticipate the impact of new direct antiviral agents.
Main Methods:
- Review of treatment strategies for Hepatitis C.
- Analysis of factors influencing sustained virological response.
- Discussion of evolving patient management protocols.
Main Results:
- Pegylated interferon and ribavirin achieve SVR in over 50% of patients.
- Treatment optimization includes dose/duration adaptation based on genotype, fibrosis, and response-guided therapy.
- Improved management of comorbidities and side effects contributes to better outcomes.
Conclusions:
- Hepatitis C treatment has evolved, with current regimens offering significant SVR rates.
- Personalized treatment approaches and proactive management of complications are key.
- Emerging direct antiviral agents are expected to further enhance SVR and alter patient management strategies.
Related Concept Videos
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:28Viral Hepatitis I: Introduction
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
01:23Cirrhosis I: Introduction
Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
01:28Esophageal Varices-II: Clinical Features and Management
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
01:22Antiviral Nucleoside Inhibitors
Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...